Retatrutide: Inside the Triple Agonist Redefining Metabolic Research
Semaglutide changed the conversation. Tirzepatide pushed it further. Now researchers are turning their attention to retatrutide — a compound that targets not two but three hormone receptors simultaneously, and is emerging as one of the most studied peptides in contemporary metabolic research.
What is Retatrutide?
Retatrutide is a triple glucagon hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors Wikipedia in a single molecule. Engineered from a GIP peptide backbone, it consists of 39 amino acids and incorporates three non-coded amino acid residues that provide stability, optimal receptor activity, and a favorable pharmacokinetic profile. ScienceDirect
What makes it distinct from predecessors is the addition of glucagon receptor agonism to the now-familiar GLP-1/GIP pairing. Each receptor plays a different role in metabolic signaling — and activating all three simultaneously is the central premise of the research interest surrounding this compound.
What Researchers Are Studying
The bulk of published research has focused on three areas:
Metabolic and weight-related pathways. Phase 2 trials showed retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity PubMed Central — results that drew significant attention from the research community given how they compare to earlier single and dual agonist compounds.
Glycemic regulation. In participants with type 2 diabetes, 77–82% achieved normal blood sugar levels and 57–63% achieved 15% or greater weight loss after 36 weeks. PubMed Central
Liver and cardiovascular biology. Because the liver is rich in glucagon receptors — unlike GLP-1 or GIP receptors — retatrutide has attracted particular interest in liver disease research, where glucagon agonism appears to ease oxidative stress in liver mitochondria. ADA Meeting News Separately, a phase 2a trial reported up to 82% reduction in liver fat. Nature
Where Research Stands
Retatrutide is currently being evaluated in multiple Phase 3 clinical trials across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic liver disease. Eli Lilly and Company It remains investigational and is not FDA approved.
Research Use Context
Dobry Peptides supplies Retatrutide strictly for laboratory and in-vitro research use. This compound is not intended for human or animal consumption and is not approved for therapeutic or clinical application. All handling should follow institutional laboratory safety standards.
Third-party tested Retatrutide is available in 10mg, 20mg, and 30mg formats. View product →